---
document_datetime: 2024-09-24 14:39:29
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/recarbrio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: recarbrio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.276449
conversion_datetime: 2025-12-19 12:10:32.628517
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Recarbrio

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0030/G            | This was an application for a group of variations. B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.1.a - Change in the specification parameters | 19/09/2024                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| and/or limits of an excipient specification limits B.III.2.a.2 - Change of non EU Pharmacopoeial with the Ph. Eur. or with a Member State - Excipient/AS B.II.c.2.d - Change in test - Other changes to a test replacement or addition) B.II.b.3.a - Change in the the finished or intermediate in the manufacturing process B.II.c.1.b - Change in the and/or limits of an excipient specification parameter corresponding test method B.II.c.1.b - Change in the and/or limits of an excipient specification parameter corresponding test method B.II.c.1.b - Change in the and/or limits of an excipient specification parameter corresponding test method B.II.c.1.b - Change in the and/or limits of an excipient specification parameter corresponding test method B.II.c.1.b - Change in the and/or limits of an excipient specification parameter   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.II.c.1.b - Change in and/or limits of an excipient specification parameter corresponding test method B.II.c.1.b - Change in and/or limits of an excipient specification parameter corresponding test method B.II.c.1.b - Change in and/or limits of an excipient specification parameter corresponding test method B.II.c.1.b - Change in and/or limits of an excipient specification parameter corresponding test method B.II.c.1.b - Change in and/or limits of an excipient specification parameter corresponding test method B.II.c.1.b - Change in and/or limits of an excipient specification parameter corresponding test method B.II.b.1.f - Replacement manufacturing site for manufacturing process manufacturing operation(s) release, batch control, sterile medicinal products aseptically manufactured)   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product                                                                                                                                                                                                                                                                                                    |            |            |                       |                                    |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------|
| R/0029              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/07/2024 | 19/09/2024 | SmPC, Annex II and PL | Renewal of marketing authorisation |
| PSUSA/10830 /202307 | Periodic Safety Update EU Single assessment - imipenem / cilastatin / relebactam                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 08/02/2024 | n/a        |                       | PRAC Recommendation - maintenance  |
| IA/0028             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 05/01/2024 | n/a        |                       |                                    |
| IA/0027/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 08/11/2023 | n/a        |                       |                                    |
| IB/0025             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                 | 29/09/2023 | n/a        |                       |                                    |

<div style=\"page-break-after: always\"></div>

| IB/0024             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                            | 27/09/2023   | n/a        |    |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|-----------------------------------|
| PSUSA/10830 /202301 | Periodic Safety Update EU Single assessment - imipenem / cilastatin / relebactam                                                                                                                                                                                                                      | 31/08/2023   | n/a        |    | PRAC Recommendation - maintenance |
| PSUSA/10830 /202207 | Periodic Safety Update EU Single assessment - imipenem / cilastatin / relebactam                                                                                                                                                                                                                      | 09/02/2023   | n/a        |    | PRAC Recommendation - maintenance |
| IB/0022/G           | This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 21/12/2022   | n/a        |    |                                   |
| N/0021              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                      | 28/11/2022   | 19/09/2024 | PL |                                   |
| IB/0020             | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                  | 10/11/2022   | n/a        |    |                                   |
| IA/0019             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                      | 27/09/2022   | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0017             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                 | 26/09/2022   | n/a   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10830 /202201 | Periodic Safety Update EU Single assessment - imipenem / cilastatin / relebactam                                                                                                                                                                                                                                                                                                                                                                                                                 | 01/09/2022   | n/a   | PRAC Recommendation - maintenance |
| IA/0016/G           | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of                              | 20/07/2022   | n/a   |                                   |
| IA/0015/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 10/06/2022   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

| WS/2193             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                    | 02/06/2022   | n/a        |    |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|-----------------------------------|
| PSUSA/10830 /202107 | Periodic Safety Update EU Single assessment - imipenem / cilastatin / relebactam                                                                                                                                                                                                                                                                                                       | 10/02/2022   | n/a        |    | PRAC Recommendation - maintenance |
| IB/0012/G           | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer | 02/12/2021   | n/a        |    |                                   |
| N/0010              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                       | 11/10/2021   | 24/03/2022 | PL |                                   |
| IB/0009/G           | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same                                                             | 16/09/2021   | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

|                     | pharmaceutical group as the currently approved manufacturer B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                  |            |            |                 |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| IB/0008/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation | 02/09/2021 | n/a        |                 |                                   |
| PSUSA/10830 /202101 | Periodic Safety Update EU Single assessment - imipenem / cilastatin / relebactam                                                                                                                                                                                                                            | 02/09/2021 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0006           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                  | 15/02/2021 | 24/03/2022 | Annex II and PL |                                   |
| PSUSA/10830 /202007 | Periodic Safety Update EU Single assessment - imipenem / cilastatin / relebactam                                                                                                                                                                                                                            | 11/02/2021 | n/a        |                 | PRAC Recommendation - maintenance |
| IB/0005             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                              | 29/01/2021 | n/a        |                 |                                   |
| II/0001             | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or                                                                                                                                                                                                              | 15/10/2020 | 16/11/2020 | SmPC, Annex     |                                   |

<div style=\"page-break-after: always\"></div>

|           | of an approved one                                                                                                             |            |     | II and PL   | modification   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|----------------|
| IAIN/0002 | B.I.e.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supportive data | 12/06/2020 | n/a |             |                |